FY2017 EPS Estimates for Eli Lilly and Company (LLY) Reduced by Jefferies Group

Eli Lilly and Company (NYSE:LLY) – Research analysts at Jefferies Group lowered their FY2017 EPS estimates for shares of Eli Lilly and in a research report issued to clients and investors on Wednesday. Jefferies Group analyst J. Holford now expects that the company will earn $4.14 per share for the year, down from their previous estimate of $4.19. Jefferies Group has a “Buy” rating and a $89.00 price target on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2020 earnings at $5.83 EPS and FY2021 earnings at $6.77 EPS.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.86 EPS.

WARNING: This piece was originally published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://transcriptdaily.com/2017/10/21/fy2017-eps-estimates-for-eli-lilly-and-company-lly-reduced-by-jefferies-group.html.

A number of other equities research analysts have also recently weighed in on LLY. BMO Capital Markets reiterated an “underperform” rating and set a $71.00 price target (down from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Piper Jaffray Companies reiterated an “overweight” rating and set a $105.00 price target (up from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research report on Monday, July 17th. Morgan Stanley reiterated a “hold” rating and set a $86.00 price target on shares of Eli Lilly and in a research report on Friday, September 15th. Finally, Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly and currently has a consensus rating of “Hold” and a consensus price target of $88.97.

Eli Lilly and (LLY) opened at 87.23 on Friday. The company’s 50-day moving average is $84.38 and its 200 day moving average is $82.29. Eli Lilly and has a one year low of $64.18 and a one year high of $89.09. The company has a market capitalization of $92.03 billion, a P/E ratio of 37.75 and a beta of 0.34.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a yield of 2.38%. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 180,000 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $81.06, for a total value of $14,590,800.00. Following the transaction, the insider now directly owns 123,865,804 shares of the company’s stock, valued at approximately $10,040,562,072.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 990,000 shares of company stock valued at $82,949,650. 0.20% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Acrospire Investment Management LLC increased its stake in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the period. MPS Loria Financial Planners LLC acquired a new position in shares of Eli Lilly and during the 2nd quarter worth $128,000. San Francisco Sentry Investment Group CA acquired a new position in shares of Eli Lilly and during the 2nd quarter worth $129,000. Heritage Trust Co acquired a new position in shares of Eli Lilly and during the 1st quarter worth $135,000. Finally, Point72 Asia Hong Kong Ltd grew its stake in shares of Eli Lilly and by 237.4% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after purchasing an additional 1,239 shares during the period. 75.53% of the stock is currently owned by institutional investors.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply